Methods of using recombinant replication-deficient cytomegalovirus (CMV) to generate a long-term, repeatedly stimulated immune response in a subject, for instance against a heterologous antigen expressed by the cytomegalovirus, are described. Also described are methods of using a recombinant replication deficient CMV as an anti-cancer immunogenic preparation.
